PubMed=1371813; DOI=10.1093/jnci/84.3.165
Hendrix M.J.C., Seftor E.A., Chu Y.-W., Seftor R.E.B., Nagle R.B., McDaniel K.M., Leong S.P.L., Yohem K.H., Leibovitz A., Meyskens F.L. Jr., Conaway D.H., Welch D.R., Liotta L.A., Stetler-Stevenson W.G.
Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential.
J. Natl. Cancer Inst. 84:165-174(1992)

PubMed=10952317; DOI=10.1038/35020115
Bittner M., Meltzer P.S., Chen Y.-D., Jiang Y., Seftor E.A., Hendrix M.J.C., Radmacher M.D., Simon R.M., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E., Wang E., Marincola F.M., Gooden G.C., Lueders J., Glatfelter A., Pollock P.M., Carpten J.D., Gillanders E.M., Leja D., Dietrich K., Beaudry C., Berens M.E., Alberts D.S., Sondak V.K., Hayward N.K., Trent J.M.
Molecular classification of cutaneous malignant melanoma by gene expression profiling.
Nature 406:536-540(2000)

PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J., Nomoto K., Pollock P.M.
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012)